Oppenheimer Weighs in on Acasti Pharma Inc’s Q1 2021 Earnings (NASDAQ:ACST)

Share on StockTwits

Acasti Pharma Inc (NASDAQ:ACST) – Research analysts at Oppenheimer issued their Q1 2021 earnings estimates for shares of Acasti Pharma in a research note issued to investors on Thursday, November 14th. Oppenheimer analyst L. Gershell expects that the biopharmaceutical company will earn ($0.10) per share for the quarter. Oppenheimer also issued estimates for Acasti Pharma’s Q2 2021 earnings at ($0.10) EPS, Q3 2021 earnings at ($0.11) EPS, Q4 2021 earnings at ($0.11) EPS and FY2023 earnings at $0.74 EPS.

ACST has been the topic of a number of other reports. B. Riley began coverage on shares of Acasti Pharma in a research note on Thursday, August 29th. They issued a “buy” rating and a $7.75 price objective on the stock. ValuEngine cut shares of Acasti Pharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 8th. Zacks Investment Research cut shares of Acasti Pharma from a “hold” rating to a “sell” rating in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating on shares of Acasti Pharma in a research note on Thursday, August 15th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.05.

Shares of NASDAQ ACST opened at $2.04 on Friday. The stock has a market cap of $181.48 million, a price-to-earnings ratio of -2.87 and a beta of 1.36. Acasti Pharma has a 52 week low of $0.60 and a 52 week high of $2.95. The company’s 50-day moving average price is $1.98 and its 200 day moving average price is $1.62.

Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.01.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sterling Investment Advisors Ltd. acquired a new stake in Acasti Pharma in the 3rd quarter valued at about $38,000. Morgan Stanley boosted its stake in shares of Acasti Pharma by 20.6% during the 2nd quarter. Morgan Stanley now owns 45,687 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 7,789 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. acquired a new stake in shares of Acasti Pharma during the 3rd quarter worth about $95,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Acasti Pharma during the 3rd quarter worth about $104,000. Finally, Bank of Montreal Can boosted its stake in shares of Acasti Pharma by 2.0% during the 2nd quarter. Bank of Montreal Can now owns 253,287 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 5,000 shares during the last quarter. 3.12% of the stock is currently owned by hedge funds and other institutional investors.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Further Reading: How to Invest in Growth Stocks

Earnings History and Estimates for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

KeyCorp Comments on Micron Technology, Inc.’s Q4 2020 Earnings
KeyCorp Comments on Micron Technology, Inc.’s Q4 2020 Earnings
Oppenheimer Weighs in on Acasti Pharma Inc’s Q1 2021 Earnings
Oppenheimer Weighs in on Acasti Pharma Inc’s Q1 2021 Earnings
SHOWA DENKO KK/ADR  vs. Its Competitors Financial Analysis
SHOWA DENKO KK/ADR vs. Its Competitors Financial Analysis
FY2020 EPS Estimates for DCC plc  Decreased by Jefferies Financial Group
FY2020 EPS Estimates for DCC plc Decreased by Jefferies Financial Group
Reviewing Conversion Labs  and Amcor
Reviewing Conversion Labs and Amcor
Norsk Hydro ASA  Downgraded by ValuEngine
Norsk Hydro ASA Downgraded by ValuEngine


© 2006-2019 Ticker Report